🇺🇸 FDA

Intelligence · Clinical Pipeline

Infectious disease · Phase I

Infectious disease programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
240

Quick answer

Infectious disease Phase I programs: NovaPharmaNews indexes 240 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 5

  1. (+)-SJ000557733

    CNS Pharmaceuticals

    Plasmodium Falciparum Malaria

    phase 1 small molecule completed

    1 trial

  2. 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV Infection

    phase 1 mab completed

    1 trial

  3. 480 mg Piperaquine phosphate

    CNS Pharmaceuticals

    Malaria

    phase 1 small molecule completed

    1 trial

  4. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

  5. A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

    Lacuna Pharma Pty Ltd

    Urinary tract infections (UTIs)/complicated UTI (cUTI)

    phase 1 other active

    1 trial

  6. A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  7. A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

    Lacuna Pharma Pty Ltd

    Severe infections caused by Gram-negative bacteria

    phase 1 other active

    1 trial

  8. A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection

    ASSEMBLY BIOSCIENCES, INC.

    chronic hepatitis B virus infection (cHBV)

    phase 1 other active

    1 trial

  9. A clinical study of MK-1289 in healthy adult men (MK-1289-001)

    Merck Sharp and Dohme

    COVID-19 Infection

    phase 1 other active

    1 trial

  10. A clinical study of MK-3508 in healthy people (MK-3508-006)

    Merck Sharp and Dohme

    Respiratory syncytial virus infection

    phase 1 other active

    1 trial

  11. A clinical study of MK-4646 in healthy people (MK-4646-002)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  12. A clinical study of MK-4646 in people with HIV (MK-4646-003)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  13. A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV

    BioNTech SE

    HIV-1 infection

    phase 1 other active

    1 trial

  14. A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

    Chongqing Precision Biotech Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  15. A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults

    Alphapharm Pty Ltd

    Sexual Transmitted Infection (STI)

    phase 1 other active

    1 trial

  16. A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections and cancers

    phase 1 other active

    1 trial

  17. A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

    Teva Pharma GmbH

    Pneumococcal infection

    phase 1 other active

    1 trial

  18. A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

    Lacuna Pharma Pty Ltd

    Sepsis and Septic Shock

    phase 1 other active

    1 trial

  19. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infection

    phase 1 other active

    1 trial

  20. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  21. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  22. A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  23. A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections, precancers and cancers

    phase 1 other active

    1 trial

  24. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  25. A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

    Centauri Biotech SL

    Bacterial Infection

    phase 1 other active

    1 trial

  26. A study to compare two different aramchol formulations in healthy volunteers.

    Galmed Pharmaceuticals

    Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

    phase 1 other active

    1 trial

  27. A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  28. A study to learn about how itraconazole affects the level of emodepside in the blood when emodepside is given as a new type of tablet to healthy participants

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial

  29. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  30. A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial

  31. A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

    Boehringer Ingelheim

    Metabolic Dysfunction-associated Steatohepatitis

    phase 1 other active

    1 trial

  32. AB-101

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 1 small molecule completed

    1 trial

  33. AB-836

    Arbutus Biopharma Corp

    Chronic Hepatitis

    phase 1 small molecule terminated

    1 trial

  34. ABI-4334

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  35. ABI-4334 Tablet

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  36. ABI-6250

    ASSEMBLY BIOSCIENCES, INC.

    Hepatitis Delta Virus

    phase 1 small molecule completed

    1 trial

  37. ABI-H2158

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    3 trials

  38. ABI-H2158 Reference Formulation

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  39. ABI-H3733

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  40. ABI-H3733 Liquid Oral Dosage Form

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  41. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  42. ALG-010133

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  43. ALG-020572

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  44. ALG-055009

    Aligos Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  45. ALG-097558

    Aligos Therapeutics

    COVID-19

    phase 1 small molecule completed

    3 trials

  46. ALG-125755

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  47. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  48. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many infectious disease Phase I programs exist?

240 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.